596 related articles for article (PubMed ID: 28789523)
1. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
2. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
[TBL] [Abstract][Full Text] [Related]
3. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
Yamamoto S; Sakurai Y; Harashima H
Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
[TBL] [Abstract][Full Text] [Related]
4. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung.
Ishitsuka T; Akita H; Harashima H
J Control Release; 2011 Aug; 154(1):77-83. PubMed ID: 21619903
[TBL] [Abstract][Full Text] [Related]
5. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.
Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H
Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898
[TBL] [Abstract][Full Text] [Related]
6. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid.
Hatakeyama H; Akita H; Ito E; Hayashi Y; Oishi M; Nagasaki Y; Danev R; Nagayama K; Kaji N; Kikuchi H; Baba Y; Harashima H
Biomaterials; 2011 Jun; 32(18):4306-16. PubMed ID: 21429576
[TBL] [Abstract][Full Text] [Related]
7. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
[TBL] [Abstract][Full Text] [Related]
8. Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles.
Yamamoto S; Kato A; Sakurai Y; Hada T; Harashima H
J Control Release; 2017 Apr; 251():1-10. PubMed ID: 28192155
[TBL] [Abstract][Full Text] [Related]
9. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
10. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system.
Sakurai Y; Hatakeyama H; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
Biol Pharm Bull; 2009 May; 32(5):928-32. PubMed ID: 19420766
[TBL] [Abstract][Full Text] [Related]
11. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.
Hatakeyama H; Ito E; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
J Control Release; 2009 Oct; 139(2):127-32. PubMed ID: 19540888
[TBL] [Abstract][Full Text] [Related]
12. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
[TBL] [Abstract][Full Text] [Related]
13. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
14. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
Kim HK; Davaa E; Myung CS; Park JS
Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
[TBL] [Abstract][Full Text] [Related]
15. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
[TBL] [Abstract][Full Text] [Related]
16. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
Suzuki Y; Ishihara H
Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
[TBL] [Abstract][Full Text] [Related]
17. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
[TBL] [Abstract][Full Text] [Related]
18. Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core.
Nakamura T; Yamada K; Fujiwara Y; Sato Y; Harashima H
Mol Pharm; 2018 Jun; 15(6):2142-2150. PubMed ID: 29668291
[TBL] [Abstract][Full Text] [Related]
19. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system.
Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Harashima H
Mol Ther; 2013 Jun; 21(6):1195-203. PubMed ID: 23568259
[TBL] [Abstract][Full Text] [Related]
20. [Development of a Novel Liposomal DDS by Manipulating Pharmacokinetics and Intracellular Trafficking for Drug Therapy and Nucleic Acid Medicine].
Hatakeyama H
Yakugaku Zasshi; 2018; 138(5):591-598. PubMed ID: 29709998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]